Pages that link to "Q51925544"
Jump to navigation
Jump to search
The following pages link to The value of antihypertensive drugs: a perspective on medical innovation (Q51925544):
Displaying 25 items.
- Effect of drug reminder packaging on medication adherence: a systematic review revealing research gaps (Q26862555) (← links)
- Changes in Hypertension Prevalence, Awareness, Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update (Q30249184) (← links)
- Multidrug punch cards in primary care: a mixed methods study on patients' preferences and impact on adherence (Q30588645) (← links)
- The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry. (Q30615846) (← links)
- Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines (Q33355842) (← links)
- The increasing value of education to health (Q35058201) (← links)
- Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model (Q35115881) (← links)
- Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States (Q35232308) (← links)
- Cost-effectiveness of hypertension therapy according to 2014 guidelines (Q35493852) (← links)
- The role of funding and policies on innovation in cancer drug development (Q35602147) (← links)
- Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. (Q36113704) (← links)
- Access to medications for medicare enrollees related to race/ethnicity: Results from the 2013 Medicare Current Beneficiary Survey (Q36212680) (← links)
- Risk factor management to prevent first stroke (Q37153566) (← links)
- Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model (Q37265528) (← links)
- Private practice perspective on conflict of interest mandates (Q37922964) (← links)
- Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval (Q39198395) (← links)
- Reducing branded prescription drug prices: A review of policy options (Q40083993) (← links)
- Epidemiological sociology and the social shaping of population health (Q44582497) (← links)
- Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD. (Q45408312) (← links)
- Opinion: the case for advertising pharmaceuticals direct to consumers (Q51822576) (← links)
- Objections to the use of cost-effectiveness analysis in the US: reflecting on 'Has the time come for cost-effectiveness analysis in US health care?'. (Q53542905) (← links)
- The welfare effects of innovative pharmaceuticals: an international perspective from the Dutch experience (Q58244375) (← links)
- Hypertension screening, awareness, treatment, and control in India: A nationally representative cross-sectional study among individuals aged 15 to 49 years (Q63683203) (← links)
- Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries (Q84328942) (← links)
- Clarifying the role of values in cost-effectiveness (Q89172695) (← links)